Vernalis : Posting of Circular and Notice of General Meeting

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

THE SECURITIES MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, UNLESS REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE 'SECURITIES ACT'), OR PURSUANT TO AN EXEMPTION FROM SUCH REGISTRATION. NO PUBLIC OFFERING OF THE SECURITIES DISCUSSED HEREIN IS BEING MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFERING OF SECURITIES FOR SALE IN THE UNITED STATES AND THE COMPANY DOES NOT CURRENTLY INTEND TO REGISTER ANY SECURITIES UNDER THE SECURITIES ACT. THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES.

26 April 2016

VERNALIS plc ('Vernalis' or the 'Company')

Posting of Circular and Notice of General Meeting

Vernalis plc (LSE: VER and 'the Company') confirms that, further to the Company's announcement this morning, copies of the Circular and Notice of General Meeting together with the Form of Proxy have been sent to shareholders today.

The Circular and Notice of General Meeting are available on Company's website atwww.vernalis.com.

As detailed in the announcement earlier today, the General Meeting will be held on 12 May 2016 at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH at 10.30 a.m.

-- ENDS -

Enquiries:

Notes to Editors

About Vernalis

Vernalis is a revenue-generating, specialty pharmaceutical company with significant expertise in drug development. The Company has three approved products: Tuzistra XR targeting the US prescription cough cold market; Moxatag , a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenesin adults and paediatric patients 12 years and older; and frovatriptan (Frova ) for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis also has significant expertise in fragment- and structure-based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo Pharmaceuticals Inc., GlaxoSmithKline, Genentech, H. Lundbeck A/S, Menarini, Novartis Institutes for BioMedical Research, Servier, Taisho Pharmaceutical Co. Ltd., and Tris.

For further information about Vernalis, please visitwww.vernalis.com.

Vernalis Forward-Looking Statements

This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its New Chemical Entity ('NCE') pipeline, the Company's ability to successfully commercialise its cough cold products and Moxatagthrough its own sales force, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of Tuzistra XR, Moxatag , frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.

Vernalis plc issued this content on 26 April 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 26 April 2016 16:25:29 UTC

Original Document: http://phx.corporate-ir.net/phoenix.zhtml?c=123393&p=irol-newsArticle&ID=2161581